国产可降解涂层西罗莫司洗脱支架临床应用的可行性和价格优势

发布时间：2018-05-25 04:13

本文选题：西罗莫司 + 支架　；参考：《中国组织工程研究》2017年06期

【摘要】：背景:国产可降解涂层西罗莫司洗脱支架(Tivoli支架)具有价格低廉的优势,其价格仅为进口左他莫司洗脱支架(Endeavor支架)的一半左右。Tivoli支架逐渐被广泛应用于临床,其安全性和有效性将被逐渐认可。目的:探讨国产Tivoli支架临床应用的可行性及对比进口Endeavor支架的价格优势。方法:选择2006年1月至2016年1月天津市职业病防治院(工人医院)心内科收治的共110例冠状动脉粥样硬化性心脏病患者,随机分为2组,分别接受Tivoli支架和Endeavor支架治疗。观察2组患者的手术即刻成功率,术前及术后1周血清C-反应蛋白水平,术后8个月冠状动脉造影结果,术后270 d时的主要不良心脏事件及支架内血栓事件的发生率。结果与结论:12组支架植入成功率均为100%;Tivoli支架患者植入术前与术后1周患者血清C-反应蛋白水平比较差异无显著性意义(P0.05);2术后8个月,Tivoli组和Endeavor组造影随访率分别为93%(52/56)和93%(50/54),支架内再狭窄的发生率分别为11%(8/52)和3%(2/50)(P=0.370);3术后270 d时随访率为100%,2组均无死亡、心肌梗死和血栓事件发生,主要不良心脏事件的发生率分别为11%(6/56)和7%(4/54)(P=1.000),均为靶病变血运重建;4结果说明,Tivoli支架在冠状动脉病变临床应用中的短期及中期疗效、生物相容性及安全性与进口左他莫司洗脱支架相似,因此其价格优势更加明显。
[Abstract]:Background: the domestic biodegradable sirolimus eluting stent Tivoli) has the advantage of low price, and its price is only about half of that of imported levotamosis-eluting stent Endeavor). Tivoli stent has been widely used in clinical practice. Its safety and effectiveness will be gradually recognized. Objective: to explore the feasibility of clinical application of domestic Tivoli stents and compare the price advantages of imported Endeavor stents. Methods: a total of 110 patients with coronary atherosclerotic heart disease admitted in Tianjin Occupational Disease Prevention and treatment Hospital (Workers Hospital) from January 2006 to January 2016 were randomly divided into two groups: Tivoli stents and Endeavor stents. The immediate success rate, serum C-reactive protein level, coronary angiography results at 8 months after operation and the incidence of major adverse cardiac events and stent thrombotic events at 270 days after operation were observed in both groups. Results and conclusion there was no significant difference in serum C-reactive protein levels before and 1 week after implantation of Tivoli stents in all 12 groups. The follow-up rates of Tivoli group and Endeavor group at 8 months after operation were not significantly different. The incidence of restenosis in the stent was 11.8 / 52, respectively, and at 270 days after operation, the follow-up rate was 100%. The incidence of major adverse cardiac events in patients with myocardial infarction and thrombus events were 11 / 6 / 56) and 7 / 4 / 54 / 1. 000 respectively. The results showed that Tivoli stent was effective in the short and medium term in the clinical application of coronary artery disease. Biocompatibility and safety are similar to those of imported levotamosis-eluting stents, so their price advantages are more obvious.
【作者单位】：天津市职业病防治院(工人医院)心内科;
【分类号】：R541.4

【相似文献】